Most of the tissue that survodutide patients lost was fat. Muscle accounted for no more than a tenth of it.
That finding turned a known number into news. Survodutide's headline, 16.6 percent average weight loss, was reported back in April ↗ when Boehringer Ingelheim released the Phase 3 topline. The full SYNCHRONIZE-1 dataset, presented at the American Diabetes Association meeting this week ↗ and published in the New England Journal of Medicine, fills in where on the body that weight came from. The answer is the part of the story a topline cannot carry.
In an MRI substudy ↗, survodutide ↗ cut visceral fat (the deep abdominal fat packed around the organs, the kind tied to heart and metabolic risk) by up to 34 percent, and liver fat by up to 63 percent. Lean mass, the muscle and organ tissue that fast weight loss tends to strip alongside fat, made up no more than 10.8 percent of the total tissue change at the top dose. Patients lost fat, and mostly the dangerous fat.
What survodutide is: a once-weekly injection that hits two receptors at once. One is the GLP-1 receptor ↗, the appetite target every modern obesity drug shares. The other is the glucagon receptor ↗, and that second arm is why the body-composition numbers look the way they do. Glucagon raises energy expenditure and pulls fat out of the liver directly, a mechanism the pure GLP-1 drugs do not have. The trial enrolled 725 adults with obesity or overweight and no diabetes, randomized to 3.6 mg, 6 mg, or placebo for 76 weeks. Placebo patients lost 3.2 percent.
The cost shows up in the dropout column. Nineteen percent of survodutide patients stopped the drug because of gastrointestinal side effects, against 2.9 percent on placebo, a discontinuation rate well above what the GLP-1 and dual GIP drugs report. The glucagon arm that sharpens the fat-loss profile also sharpens the nausea. Lee Kaplan, who directs an obesity institute in Boston, put the framing plainly in the company's materials: for obesity, weight loss is only part of the story.
That part of the story is what the glucagon-receptor work tracks across peptidemodel, where survodutide's liver-directed effects also topped a MASLD fibrosis network meta-analysis last month ↗. A companion trial, SYNCHRONIZE-MASLD, was published alongside the obesity data in Nature Medicine.
The obesity field has spent two years competing on a single axis: total percent lost. Survodutide's 16.6 percent sits in the middle of that pack. Its body-composition data is an argument that the axis is too narrow, that where the fat leaves from, and whether the muscle stays, will matter as much as the headline percentage once people take these drugs for decades.